While BridgeBio Pharma Inc has underperformed by -1.65%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BBIO rose by 84.58%, with highs and lows ranging from $54.60 to $21.72, whereas the simple moving average jumped by 31.62% in the last 200 days.
On July 30, 2025, Raymond James started tracking BridgeBio Pharma Inc (NASDAQ: BBIO) recommending Outperform. A report published by Truist on July 21, 2025, Initiated its previous ‘Buy’ rating for BBIO. Jefferies also rated BBIO shares as ‘Buy’, setting a target price of $70 on the company’s shares in an initiating report dated July 14, 2025. Wolfe Research initiated its ‘Outperform’ rating for BBIO, as published in its report on June 17, 2025. Redburn Atlantic’s report from March 31, 2025 suggests a price prediction of $50 for BBIO shares, giving the stock a ‘Buy’ rating. Scotiabank also rated the stock as ‘Sector Outperform’.
Analysis of BridgeBio Pharma Inc (BBIO)
Further, the quarter-over-quarter increase in sales is 4999.86%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of BridgeBio Pharma Inc’s future performance, with equity being one of the most critical indicators. Taking into account the quick ratio of the company, currently set at 5.08, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and BBIO is recording an average volume of 2.77M. On a monthly basis, the volatility of the stock is set at 3.93%, whereas on a weekly basis, it is put at 3.18%, with a loss of -1.04% over the past seven days. Furthermore, long-term investors anticipate a median target price of $66.37, showing growth from the present price of $50.65, which can serve as yet another indication of whether BBIO is worth investing in or should be passed over.
How Do You Analyze BridgeBio Pharma Inc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 15.13%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 89.31% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
